The good news just keeps rolling in for AstraZeneca’s Tagrisso--and this time, it’s in the form of positive Phase III data. The British pharma giant announced on Monday that its AURA3 trial--which ...

After a massive tumor progression showing, AstraZeneca hopes new life extension data could expel whatever doubt that remains for using Tagrisso early in non-small cell lung cancer (NSCLC). Using ...

A U.S. appeals court on Thursday upheld a ruling for AstraZeneca against allegations that its ​blockbuster lung-cancer drug Tagrisso infringed patents owned by ‌Pfizer subsidiary Wyeth.

The FDA will speed up its review of Tagrisso plus chemotherapy for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer after the regimen led to improved outcomes in a phase 3 ...

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

Tagrisso (osimertinib) was granted a Breakthrough Therapy Designation for the firstline treatment of patients who have metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). Tagrisso ...

Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...

The best treatment for a genetically driven form of lung cancer continues to show lasting benefits, a new clinical trial update shows. After four years of follow-up, disease-free survival was 73% in ...

LONDON, June 4 (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have ...